These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1109 related items for PubMed ID: 15649162
1. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? Bulutcu FS, Ozbek U, Polat B, Yalçin Y, Karaci AR, Bayindir O. Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162 [Abstract] [Full Text] [Related]
2. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R. Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201 [Abstract] [Full Text] [Related]
3. Tranexamic acid as a means of reducing the need for blood and blood component therapy in children undergoing open heart surgery for congenital cyanotic heart disease. Vacharaksa K, Prakanrattana U, Suksompong S, Chumpathong S. J Med Assoc Thai; 2002 Sep; 85 Suppl 3():S904-9. PubMed ID: 12452228 [Abstract] [Full Text] [Related]
4. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O. J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414 [Abstract] [Full Text] [Related]
5. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Jamieson WR, Dryden PJ, O'Connor JP, Sadeghi H, Ansley DM, Merrick PM. Circulation; 1997 Nov 04; 96(9 Suppl):II-96-100; discussion II-100-1. PubMed ID: 9386082 [Abstract] [Full Text] [Related]
6. [Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery]. Yasim A, Aşik R, Atahan E. Anadolu Kardiyol Derg; 2005 Mar 04; 5(1):36-40. PubMed ID: 15755701 [Abstract] [Full Text] [Related]
7. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M. Eur J Cardiothorac Surg; 2005 Oct 04; 28(4):563-8. PubMed ID: 16125959 [Abstract] [Full Text] [Related]
8. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Baric D, Biocina B, Unic D, Sutlic Z, Rudez I, Vrca VB, Brkic K, Ivkovic M. Eur J Cardiothorac Surg; 2007 Mar 04; 31(3):366-71; discussion 371. PubMed ID: 17218108 [Abstract] [Full Text] [Related]
10. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, Geissler HJ, Mehlhorn U. Curr Med Res Opin; 2004 Jan 04; 20(1):121-6. PubMed ID: 14741082 [Abstract] [Full Text] [Related]
12. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Breuer T, Martin K, Wilhelm M, Wiesner G, Schreiber C, Hess J, Lange R, Tassani P. Eur J Cardiothorac Surg; 2009 Jan 04; 35(1):167-71; author reply 171. PubMed ID: 19027313 [Abstract] [Full Text] [Related]
13. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass. Waldow T, Krutzsch D, Wils M, Plötze K, Matschke K. Clin Hemorheol Microcirc; 2009 Jan 04; 42(4):269-77. PubMed ID: 19628892 [Abstract] [Full Text] [Related]
14. Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation. Verma YS, Chauhan S, Bisoi AK, Gharde P, Kiran U, Das SN. Ann Card Anaesth; 2010 Jan 04; 13(2):110-5. PubMed ID: 20442540 [Abstract] [Full Text] [Related]
15. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery. Vonk AB, Meesters MI, Schats J, Romijn JW, Jansen EK, Boer C. Interact Cardiovasc Thorac Surg; 2011 Feb 04; 12(2):135-9. PubMed ID: 21075830 [Abstract] [Full Text] [Related]
16. Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls. Baldus CR, Bridwell KH, Lenke LG, Okubadejo GO. Spine (Phila Pa 1976); 2010 Jan 15; 35(2):235-9. PubMed ID: 20081519 [Abstract] [Full Text] [Related]
17. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Spine (Phila Pa 1976); 2008 Nov 15; 33(24):2577-80. PubMed ID: 19011538 [Abstract] [Full Text] [Related]
18. Antifibrinolytic therapy in complex spine surgery: a case-control study comparing aprotinin and tranexamic acid. Colomina MJ, Bagó J, Vidal X, Mora L, Pellisé F. Orthopedics; 2009 Feb 15; 32(2):91. PubMed ID: 19301800 [Abstract] [Full Text] [Related]
19. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Ickx BE, van der Linden PJ, Melot C, Wijns W, de Pauw L, Vandestadt J, Hut F, Pradier O. Transfusion; 2006 Apr 15; 46(4):595-605. PubMed ID: 16584436 [Abstract] [Full Text] [Related]
20. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. Anesth Analg; 2010 Jan 01; 110(1):21-9. PubMed ID: 19910626 [Abstract] [Full Text] [Related] Page: [Next] [New Search]